Early mortality following COVID-19 infection among cancer patients who received radiotherapy: a meta-analysis

Mona Kamal1,2†, Massimo Baudo3, Shon Shmushkevich4, Yimin Geng5 and Mohamed Rahouma6

1Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 3Department of Cardiac Surgery, Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 4Department of Cardiothoracic Surgery, Weill Cornell Medicine/New York–Presbyterian Hospital, New York, USA; 5Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA and 6Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

Abstract

Introduction: Identifying the patients at higher risk for poor outcomes after radiotherapy (RT) during coronavirus disease 19 (COVID-19) era is an unmet clinical need.

Methods: The Ovid MEDLINE, Ovid Embase, Clarivate Analytics Web of Science, PubMed and Wiley-Blackwell Cochrane Library databases were searched. Eligible studies were required to address the outcomes of cancer patients who underwent RT during the COVID-19 era. The primary outcome was early mortality, while secondary outcomes included length of hospital stay, hospital admission, intensive care unit (ICU) admission and use of mechanical ventilation. Pooled event rates were calculated, and meta-regression and ‘leave-one-out’ sensitivity analyses were performed.

Results: Twelve eligible studies were included out of 928. The prevalence of early mortality after COVID-19 infection was 21.0%. The prevalence of hospital admission, ICU admission and mechanical ventilation was 78.1%, 15.4% and 20.0%, respectively. Meta-regression showed that older age was significantly and positively associated with early mortality ($\beta = 0.0765 \pm 0.0349$, $p = 0.0284$), while breast cancer was negatively associated with early mortality ($\beta = -1.2754 \pm 0.6373$, $p = 0.0454$).

Conclusions: Older age adversely impacts the early mortality rate in cancer patients during COVID-19 era. The risks of interruption/delay of cancer treatment should be weighed against the risk of increased morbidity and mortality from the infection. A global registry is needed to establish international oncologic guidelines during the COVID-19 era.

Introduction

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacts clinical care worldwide.1,2 Thus, wide-scale recommendations and guidelines have been issued by several international health care organisations to optimise clinical care during this pandemic.3–6 Nevertheless, cancer patients require focused and individually optimised care plans considering their vulnerability and unavoidable immunocompromised status.7 These emerging care plans for cancer patients need to be supported by evidence-based data based on timely follow-up of their oncologic outcomes during the SARS-CoV-2 pandemic.

Data showed that cancer patients have a higher risk of coronavirus disease 19 (COVID-19) infection with subsequently higher morbidity and mortality.8–10 Also a challenge is protecting health care providers from COVID-19 and optimising care resources while the pandemic increases demand.11 In particular, shortages of chemotherapy and disruption of other medical product supply chains during the pandemic were found to impact oncologic outcomes.11,12 Another impact on cancer patients is that enrolment and follow-up of patients on clinical trials have been affected during the pandemic; protocol deviations are occurring more often.13,14

The available outcomes data from oncologic centres are scant and lack follow-up time.15 Additionally, we could not ignore the impact of different medical care plans across the globe in comparing oncologic outcomes. To obtain robust data and optimise oncologic care plans during COVID-19 era, we need detailed evaluation and interrogation of the available data among cancer patients. Such an effort would help minimise the risk of infection, improve outcomes and optimise clinical resource allocation for cancer populations. This effort is also critical for patient prioritisation, multidisciplinary team involvement and selection of alternative substitute care plans and therapies.16
While telemedicine may help overcome some of the abovementioned challenges, radiotherapy (RT) as a key component of cancer therapy represents a special challenge. RT requires regular, often daily, treatments; patients need to be driven to the centre and treatment requires the presence of therapeutic radiographers, physicists and physicians. Furthermore, since patients frequently use the same machine, the time necessary to prepare the equipment for each individual patient presents another challenge. Also, RT may increase the risk of COVID-19 owing to RT-induced immunodeficiency and may increase morbidity due to RT-induced toxicities, for instance, intestinal pneumonitis. The picture may worsen if the patient is receiving concurrent chemotherapy/immunotherapy and RT. Herein, we are focusing on studies that addressed the impact of COVID-19 infection on cancer patients receiving RT.

**Methods**

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

**Search strategy**

The Ovid MEDLINE, Ovid Embase, Clarivate Analytics Web of Science, PubMed and Wiley-Blackwell Cochrane Library databases were searched for publications in the English language from 1 December 2019 to 1 September 2020. The following concepts were searched for using subject headings and keywords as needed: ‘COVID-19’, ‘severe acute respiratory syndrome coronavirus 2’, ‘SARS-CoV-2’, ‘coronavirus infections’, ‘novel coronavirus’, ‘cancer’, ‘neoplasms’, ‘tumor’, ‘leukemia’, ‘lymphoma’, ‘melanoma’, ‘carcinoma’, ‘sarcoma’, ‘oncology’, ‘radiotherapy’, ‘radiation’, ‘chemoradiotherapy’, ‘proton therapy’, ‘radiosurgery’, ‘brachytherapy’, etc. The search terms were combined by `or` if they represented similar concepts and combined by `and` if they represented different concepts. The complete MEDLINE search strategy is detailed in Supplementary Table 1.

**Study selection and inclusion criteria**

Within the results yielded by the search strategy above, we searched original studies (case reports, case series and observational studies). To be eligible, studies were required to address measurable outcomes (early mortality, hospital admission, intensive care unit [ICU] admission and mechanical ventilation) in cancer patients who underwent RT during the COVID-19 era. There was no exclusion based on patient age, sex or type of cancer. Other forms of publications including review articles, editorials, letters, guidelines, experience pieces, comments, consensus publications, abstracts and conference papers were excluded. Preprints and articles with not enough information or addressing irrelevant topics were also excluded.

**Data extraction and statistical analysis**

Microsoft Office 365 Excel software was used for data extraction. Categorical variables were expressed as frequency, while continuous variables were reported as mean with standard deviation. The following variables were extracted from the included papers: publication year, country where the patients were treated, sample size, mean age, male percentage, chronic obstructive pulmonary disease, diabetes, hypertension, chronic cardiovascular and cerebrovascular disease, chronic liver disease, type of additional therapy (surgery, chemotherapy, hormonal therapy, immunotherapy, targeted therapy), type of cancer, hospital mortality, length of hospital stay, hospital admission, ICU admission and use of mechanical ventilation. The primary outcome was early mortality, while secondary outcomes include length of hospital stay, hospital admission, ICU admission and use of mechanical ventilation.

The pooled event rates with 95% confidence intervals (CIs) were calculated using the DerSimonian–Laird (inverse variance) method. Meta-regression was performed to explore the effect of patients’ characteristics on early mortality. Studies were weighted by the inverse of the variance of the estimate for that study, and between-study variance was estimated with the DerSimonian–Laird estimator. The results were reported as the regression coefficient (i.e. beta).

Hypothesis testing for equivalence was set at the 2-tailed 0.05 level. Heterogeneity was based on the Cochran Q test, with $I^2$ values. For the primary outcome, in the case of high heterogeneity ($I^2 > 75%$), individual study inference analysis was performed through a ‘leave-one-out’ sensitivity analysis. Graphical inspection of funnel plots and the Egger regression test were used for assessment of publication bias. The quality of the included studies was assessed using the Newcastle–Ottawa scale. All analyses were performed using R version 3.3.3 (R Project for Statistical Computing) using the ‘meta’ and ‘metafor’ statistical packages within RStudio.

**Results**

**Studies selected and data extracted**

The systematic review process according to the PRISMA guidelines is outlined in Figure 1. The literature search identified 928 potentially eligible studies. No additional articles were identified through backward snowballing. After removal of duplicates, 505 studies were screened. After exclusion of records, based on title and abstract, according to topic, publication type and further duplication, 40 full-text articles were assessed for eligibility according to population and outcomes studied. Twelve articles met our inclusion criteria with a total of 1224 patients with cancer who underwent RT during the pandemic, with measurable outcomes available. All studies were published in 2020, and the sample size ranged from 1 to 800. Details of the individual studies are shown in Table 1.

Overall, fever (54.5%), cough (42.2%) and dyspnoea (30.6%) were the most commonly presenting symptoms. Suspected hospital-associated transmission of COVID-19 was a frequent observation. Known COVID-19 symptoms, radiologic features and laboratory anomalies were helpful for diagnosing the infected cases. Commonly observed laboratory abnormalities included lymphopaenia, hypoproteinaemia, anaemia and elevation of C-reactive protein, lactate dehydrogenase, D dimer and erythrocyte sedimentation rate, as well as anaemia. Most of the infected cases had comorbid conditions and had received cancer therapy shortly before the COVID-19 infection. The most common cancer types were breast cancer (18.3%), haematologic malignancies (13.8%), gastric cancer (3.8%) and lung cancer (3.6%); a substantial portion was metastatic (Table 1).

Zhang et al. found that receipt of cancer therapy within 14 days, presence of patchy consolidation on CT and stage IV increased the risk of poor outcomes. Dai et al. showed that
diagnosis of haematologic malignancies and lung cancer as well as stage IV increased the risk of death, ICU admission, infection severity and the need for invasive ventilation. Additionally, Lee et al. found that death rates were higher in patients who were male, who were of advanced age or who had comorbidities, with odds ratios of 2.3, 9.4 and 1.7, respectively.26 Also, Angelis et al. identified factors associated with a higher risk of severe COVID-19 infection, including receipt of cancer therapy and presence of inflammatory infiltrates on chest CT. Furthermore, Kabarriti et al. found that mean RT dose to the lungs, recent history of RT (within 1 month to 1 year) and diagnosis of lung cancer were significantly associated with increased risk of death.22 More details are given in Supplementary Tables 2 and 3.

**Meta-analysis**

The prevalence of early mortality after COVID-19 infection was 21.0% (95% CI: 15.9%, 27.1%) (Figure 2). All 12 studies were used to obtain this result, with all 1224 patients included. A high level of heterogeneity was present among the included studies ($I^2 = 52.8\%$, $p = 0.016$). Leave-one-out analysis is depicted in Supplementary Figure 1. Visual inspection of the funnel plot and the Egger test did not reveal significant asymmetry (Egger test $p = 0.108$; Supplementary Figure 2), suggesting no significant publication bias for the analysis. Subgroup analysis based on the percentage of patients who received RT revealed a higher incidence of early mortality (0.2218 [95% CI: 0.1561, 0.3050]) compared with that in the remaining studies (0.1990 [95% CI: 0.1318, 0.2890]) in the remaining studies, but the interaction $p$ value was not statistically significant ($p = 0.6814$, Table 2 and Supplementary Figure 3).

The prevalence of hospital admission was 78.1% (95% CI: 43.9%, 94.2%) (Supplementary Figure 4). This prevalence was derived from 5 of the included studies, with a total of 179 patients included. A high level of heterogeneity was present among these included studies ($I^2 = 87.5\%$, $p < 0.01$).

The prevalence of ICU admission was 15.4% (95% CI: 9.3%, 24.5%) (Supplementary Figure 5). Five studies were used to obtain this result, with a total of 309 patients included. A high level of heterogeneity was present among these included studies ($I^2 = 59.3\%$, $p = 0.043$).

The prevalence of mechanical ventilation was 20.0% (95% CI: 5.2%, 53.6%) (Supplementary Figure 6). This result was derived from 2 of the included studies, with a total of 133 patients included. A high level of heterogeneity was present among these included studies ($I^2 = 89.4\%$, $p = 0.002$).

The outcomes are summarised in Table 2.
Table 1. Overview of included patients

| Study          | N   | Age       | Male Gender | Hypertension | Diabetes | COPD | Chemotherapy | Radiotherapy | Surgery | Immunotherapy | Targeted Treatment | Lung Cancer | Breast Cancer | Gastric cancer |
|----------------|-----|-----------|-------------|--------------|----------|------|--------------|--------------|---------|---------------|---------------------|-------------|---------------|-----------------|
| Angelis et al. | 113 | 66 y      | 63 (55-75%) | 39 (34-5%)   | 18 (15-9%) | 6(4%) | 58 (52-2%)   | 11 (9-7%)    | NA      | 4 (3-5%)       | NA                  | NA          | 18 (16%)      | 32 (28-31%)    |
| Dai et al.     | 105 | 64 y      | 57 (54-3%)  | 30 (28-6%)   | 7 (6-7%)  | NA   | 17 (16-19%)  | 13 (12-38%)  | 8 (7-62%) | 6 (5-71%)      | 4 (3-8%)            | 22(21%)     | 11 (10-48%)    | 13 (12-38%)    |
| Grelli et al.  | 1   | 73 y      | 0 (0%)      | 1 (100%)     | NA        | NA   | 1 (100%)     | 1 (100%)     | 1 (100%) | NA            | NA                  | NA          | 1 (100%)      | NA             |
| Guerini et al. | 1   | 75 y      | 1 (100%)    | 1 (100%)     | NA        | 1 (100%) | 1 (100%)     | NA           | NA      | NA            | 1 (100%)            | NA          | NA            | NA             |
| Kabarriti et al.| 107 | 70 y      | 53 (49-5%)  | NA           | NA        | NA   | 107 (100%)   | NA           | NA      | NA            | 14 (13%)            | 28 (26%)    | NA            | NA             |
| Lee et al.     | 800 | 69 y      | 449 (56-13%)| 247 (31%)    | 131 (16%) | 61 (8%) | 281 (35%)    | 76 (10%)     | 29 (4%)  | 44 (6%)       | NA                  | 102 (13%)  | NA            | NA             |
| Samson et al.  | 3   | 64.5 y    | 0 (0%)      | NA           | NA        | 1 (33%) | NA           | 3 (100%)     | NA      | NA            | NA                  | NA          | NA            | NA             |
| Shweta et al.  | 1   | 47 y      | 1 (100%)    | NA           | NA        | NA   | 1 (100%)     | 1 (100%)     | NA      | NA            | NA                  | NA          | NA            | NA             |
| Song et al.    | 4   | 54.25 y   | 2 (50%)     | 1 (25%)      | NA        | 1 (25%) | 2 (50%)      | 1 (25%)      | 3 (75%)  | NA            | NA                  | NA          | 1 (25%)       | NA             |
| Spezzani et al.| 1   | 60 y      | 0 (0%)      | NA           | NA        | NA   | 1 (100%)     | 1 (100%)     | NA      | NA            | NA                  | NA          | 1 (100%)      | NA             |
| Vuagnat et al. | 59  | 58 y      | NA          | 21 (36%)     | 10 (17%)  | NA   | 29 (49-15%)  | 4 (6-78%)    | 3 (5%)   | NA            | 19 (32-2%)          | NA          | 59 (100%)     | NA             |
| Zhang et al.   | 28  | 65 y      | 17 (60-7%)  | NA           | 4 (14-3%) | 1 (3-6%) | 25 (89-3%)   | 25 (89-3%)   | 21 (75%) | 6 (21-4%)     | 6 (21-4%)           | 7 (25%)     | 3 (10-7%)     | 1 (3-6%)       |

COPD, chronic obstructive pulmonary disease; NA, not available or applicable. Values are no. (%) unless indicated otherwise.
Meta-regression

In the meta-regression analysis, older age was significantly and positively associated with early mortality ($\beta = 0.0765 \pm 0.0349$, $p = 0.0284$), while breast cancer was negatively associated with early mortality ($\beta = -1.2754 \pm 0.6373$, $p = 0.0454$). Early mortality did not show any significant association with any other preoperative variable on meta-regression. Meta-regression outcomes are summarised in Table 3.

Assessment of the quality of the included studies using the Newcastle–Ottawa is shown in Table 4.

Discussion

In our meta-analysis of cancer patients who were underwent RT during COVID-19 era, older age adversely impacted early mortality. Thus, oncologic care strategies including RT should account for the increased risk of morbidity and mortality due to COVID-19 alongside the risks of delays in cancer treatment due to the infection and pandemic-related modifications.

During the COVID-19 pandemic, timely cancer diagnosis and tailored treatments should be maintained without jeopardising patients’ treatment outcomes while also maintaining patient’s and care providers’ safety. The optimal timing and plans for cancer treatment and follow-up must be evaluated against the vulnerability of cancer patients to morbidities and mortality after COVID-19 infection. Thus, alternative oncologic procedures and plans during COVID-19 era that ensure safety for patients and providers need to be evaluated on an individual level.\textsuperscript{32–34}

Although deaths have been observed less frequently after COVID-19 compared with SARS-CoV or MERS-CoV, COVID-19 is more transmissible, with each new COVID-19 case producing an average of three new secondary cases.\textsuperscript{35} For reducing exposure and spread of COVID-19 during the lockdown, the abovementioned care options are not always feasible.

Changes in cancer care have been observed as a result. In-person follow-up visits have been frequently replaced by teleconsultation, while physical examinations have been postponed. In addition, more treatments have been delayed or interrupted, and even if they are performed, the route of administration and length has been frequently modified.\textsuperscript{25} Furthermore, the number of cancer patients undergoing surgeries, laboratory analyses and imaging was reduced by 22–27%, the number receiving RT decreased by 8% and the number receiving immunotherapy decreased by 16%, compared to the same period last year. Meanwhile, the use of oral chemotherapy increased by 6%.\textsuperscript{25} Finally, patient recruitment in non-COVID-19 clinical trials has been significantly reduced. Such changes have been made to address the concerns regarding higher susceptibility of cancer patients to severe events after COVID-19 infection.\textsuperscript{27} A Chinese nationwide analysis shows that cancer patients are more vulnerable and at higher risk for severe complications and mortality during this pandemic.\textsuperscript{7} There is also the special, challenging scenario of co-occurrence of RT-induced lung damage and the detrimental COVID-19-related lung injury.

In the current meta-analysis, which focuses on outcomes after RT during COVID-19 era, we found higher prevalence of hospital and ICU admission, need for mechanical ventilation and early mortality.
mortality in cancer patients. Furthermore, we performed meta-
regression to analyse possible risk factors associated with early
mortality in COVID-19 affected cancer patients. The age and
breast cancer diagnosis found to be significantly associated with
early mortality.

The importance of monitoring and follow-up of the imaging
findings has been highlighted in many reports. COVID-19 has
characteristic imaging findings (bilateral lung involvement of
ground-glass opacity; lesions mainly located peripherally and
under the adjacent pleura with diffuse distribution; interlobular/
septal/pleural thickening, while some patients present with patchy
consolidation that may progress later), and the persistence or
resolution of these findings has prognostic value in predicting
the disease course and outcomes.28,36

The presence of comorbidities was a consistent risk factor for
poor outcomes in several studies.26-28 This finding has been
supported by many other reports.27,38 Additionally, advanced
age has previously been identified as a predictor of poor outcomes
in cancer patients with COVID-19.35 Patients with metastatic
status were similarly at higher risk for severe events.27,28 Our
previous meta-analysis concluded that comorbidities significantly
increase the hospital mortality rate, yet age was not a predictor for
higher mortality rate in cancer patients during the COVID-19
era.29 This difference could be explained by differences in inclusion
criteria, research questions and study duration.

The included reports in the current meta-analysis analysed the
association of cancer type with oncologic outcomes.24,27 The most
frequent cancer types were breast, haematologic, gastric and lung
malignancies. Regarding breast cancer, two of the included studies
have reported that breast cancer patients do not appear to be at
higher risk of mortality from COVID-19 and have similar clinical
and radiologic features of COVID-19, compared with the general
population,24 and that breast cancer patients have the lowest
COVID-19 infection severity and death rates among all patients
with cancer.27 On the other hand, lung cancer is reported to have
a more severe and longer disease course in SARS-CoV-2-infected
patients,27 as are haematologic cancers, probably because of the
decreased immunity associated with haematologic malignancies.27
However, in the present analysis, we were not able to sustain the
previous statements.

The onset of dyspnoea due to COVID-19 was observed
earlier in the course of infection in patients with lung cancer
compared to the general population as well as compared to
other cancer types.20,46 In patients with lung cancer, the
cancer-related respiratory difficulties and the co-occurrence of
COVID-19-associated and RT-induced interstitial pneumonitis
require special monitoring and early management.41,42 To address
the impact of RT dose on the risk of poor outcomes after COVID-
19, Kabarriti et al.22 included 107 cancer patients on RT in their
study. They found that mean RT dose to the lungs, diagnosis of
lung cancer and receipt of RT 1 month to 1 year before the
COVID-19 diagnosis were predictors of a high risk of
death. Prior RT was found to be associated with higher mortality
risk (approximately 35%) in cancer patients. A mean lung
RT dose of 7 Gy increased the risk of death after COVID-19 by
50%, while 15 Gy increased the mortality rate to approximately
75%. Of note, lung V20Gy and lung V5Gy showed similar predictive
value to that of mean lung dose. RT injuries lung tissues and
initiates cytokine release with subsequent inflammation and
fibrosis,43 thus, indication, timing and lung volume definition
should be personalised when RT cannot be delayed in high-risk
patients.

The combined effect of lung injury induced by RT, chemo-
therapy and/or immunotherapy and by COVID-19 is a challenge
in patients with breast cancer as well. In a case report by Grellier
et al. of a breast cancer patient who received 35 Gy on a moderate
hypofractionated schedule,29 the extent of the typical COVID-19
lung damage was significantly correlated with the irradiated lung
volume. Given the lack of data that address the effect of RT on the
severity of COVID-19-related lung injury, it is important to care-
fully monitor the cancer patients in need of RT that partly involves
the lungs, such as RT of the whole breast and nodal areas. Options
such as a prone or lateral position and a breathing-gated or hypo-
fractionated schedule may help reduce RT-induced lung injury.37,44

### Table 3. Meta-regression results showing effects of different variables on the early mortality outcome

| Variable                                      | Beta ± standard error, p value |
|-----------------------------------------------|--------------------------------|
| Older age                                     | 0.0765 ± 0.0349, p = 0.0284   |
| Male                                          | 0.0094 ± 0.0150, p = 0.5326   |
| Chemotherapy                                  | 0.8527 ± 0.9171, p = 0.3525   |
| Radiotherapy                                  | 0.3182 ± 0.4733, p = 0.5013   |
| Surgery                                       | 1.0071 ± 1.1642, p = 0.3870   |
| Hormone therapy                               | NA                            |
| Immunotherapy                                 | 1.9158 ± 3.9553, p = 0.6290   |
| Targeted treatment                            | −2.2250 ± 4.0353, p = 0.5814  |
| Chronic obstructive pulmonary disease         | −0.3092 ± 1.5954, p = 0.8463  |
| Diabetes                                      | 6.9133 ± 6.1997, p = 0.2648   |
| Chronic cardiovascular and cerebrovascular disease | NA                        |
| Chronic liver disease                         | NA                            |
| Hypertension                                  | 0.4453 ± 1.7971, p = 0.8043   |
| Lung cancer                                   | 0.3660 ± 2.0455, p = 0.8580   |
| Oesophagus cancer                             | NA                            |
| Breast cancer                                 | −1.2754 ± 0.6373, p = 0.0454  |
| Laryngeal carcinoma                           | NA                            |
| Liver cancer                                  | NA                            |
| Prostate cancer                               | NA                            |
| Cervical cancer                               | NA                            |
| Gastric cancer                                | 0.4635 ± 4.8552, p = 0.9239   |
| Colon cancer                                  | NA                            |
| Rectal cancer                                 | NA                            |
| Nasopharyngeal cancer                         | NA                            |
| Endometrial cancer                            | NA                            |
| Ovarian cancer                                | NA                            |
| Carcinoma of testis                           | NA                            |
| Thyroid cancer                                | NA                            |
| Blood cancer                                  | NA                            |

NA, not available/applicable.
Significant p value: ≤ 0.05.
Yet, these alternatives are not feasible nor adequate for high-risk patients who require full nodal coverage. Of note, Vuagnat et al.24 found no association between prior RT or RT sequelae and either radiologic extent of COVID-19 disease or COVID-19 outcome in breast cancer patients and found that the clinical and radiologic features of COVID-19 in these cases were similar to those previously described in non-cancer COVID-19 patients.

On the other hand, with the growing use and promising outcomes of immunotherapy, immunotherapy-induced pneumonitis (ITIP) is another challenge during the COVID-19 era, as patients on immunotherapy are more vulnerable to COVID-19, and the presenting symptoms and image features of ITIP may delay the diagnosis of COVID-19 and challenge care providers during follow-up and management.45,46 ITIP may recall RT-induced lung injury and augment the detrimental cytokine release induced by COVID-19.47,48 Additionally, the main treatment for ITIP is steroids and immunosuppressant agents, which again add challenges to diagnosis and management of COVID-19 infection.49 The case presented by Guerini et al.30 is an example of such challenges in a patient with lung cancer after concurrent chemoradiation therapy and during maintenance immunotherapy who contracted a COVID-19 infection. Unfortunately, the patient died.

Dai and colleagues27 reported the highest death rate in oncologic patients treated with immunotherapy compared to those given other treatments in their study, possibly due to a stronger cytokine storm. This result was drawn from a small group of patients, though, and our meta-analysis was not able to reach any significant association between treatment type and early mortality. Also, Song et al.23 found that patients with severe COVID-19 infection had sequestration of lymphocytes in the lungs and other organs, with resultant low counts of CD3+ CD4+ helper T cells. These findings align with other current data that associate the severity of COVID-19 infection with low T-cell counts.50,51 Another report showed that increased levels of IL-6, IL-10, IL-2 and IFN-γ in peripheral blood were associated with COVID-19 infection severity.52

The types of treatment given also need to be considered in terms of their potential association with the risk of severe events. Dai et al. found that RT alone did not affect this risk compared with the risk of these events in the general population, yet surgery increased this risk and further increased the risk of death, ICU admission and use of invasive ventilation.27 Dai et al. also showed that receipt of immunotherapy is associated with a trend towards an increased risk of severe COVID-19-related symptoms. Furthermore, Angelis et al.25 showed that receipt of chemotherapy was associated with a modest risk of severe COVID-19 infection. They also adjusted for clinical factors and categorised the chemotherapy as palliative and non-palliative. However, they mentioned in their Discussion that ‘ withholding effective cancer therapy runs the very real risk of increasing cancer morbidity and mortality, perhaps much more so than COVID-19 itself’.26 The absence of a significant negative impact of chemotherapy on morbidities and mortalities after COVID-19 infection has been shown in some larger studies as well as in Vuagnat et al.24,53 Yet, Vuagnat et al.24 observed that patients with early breast cancer who died had been treated for a systemic disease by a CTLA-4 signalling modulator. Thus, individualised decisions are warranted, and many guidelines have been published.54

The timing of anticancer therapy was found to impact the risk of severe events.23,24 Zhang et al.28 found that receipt of anticancer therapy within the past 14 days increases the risk of poor mortality after COVID-19 infection. However, Lee et al.26 found that receipt of chemotherapy, immunotherapy, hormonal therapy, targeted therapy or RT within the past 4 weeks did not impact death rates in cancer patients receiving treatment during COVID-19 era. Yet, the numbers of patients who had received immunotherapy, hormonal therapy, targeted therapy and RT were small. The timing of RT was also addressed by Kabarriti et al.,22 and they found that receiving RT within the past 1 month to 1 year increased the severity of infection and mortality rate in cancer patients during the COVID-19 era, as this period overlaps with the acute phase of development and progression of the interstitial pneumonitis induced by RT.43,55

Importantly, Shweta et al.31 highlight additional crucial issues that need to be addressed while following cancer patients with COVID-19 infection: sense of loneliness, inability to handle their own needs away from their caregivers, and the fear and worries about false-negative polymerase chain reaction test results as well as false-positive results. This uncertainty about test results is exacerbated by the fact that cancer patients usually experience similar symptoms to those of patients with COVID-19, including dyspnoea, fever, cough and fatigue, and many cancer patients may have similar imaging features to those of COVID-19 patients. Cancer patients with COVID-19 need psychological and social support, which is as much as import as medical support.

Limitations of the included studies include that some are retrospective, nonrandomised studies with small sample sizes and short follow-up. Another limit is the heterogeneous data concerning the tumour types and treatments received; however, the differences in these features allowed us to address these features as potential predictors. Some detailed useful data are lacking owing to the urgency of publishing reports to guide clinical decisions in cancer care during the COVID-19 era. Such an urgent need to publish data pressures some authors to submit their publications as editorials, letters and conference papers, which were excluded from this meta-analysis, as were reprints. Also, none of the included studies address the issue of false-negative and +positive polymerase chain reaction tests, which may under- or over-report total COVID-19 cases in patients with cancer. Furthermore, the difference in cancer practice guidelines across the globe and inherent genetic and racial differences limit the generalisation of the results. Thus, creating a dedicated and coordinated global registry of COVID-19 cases in

---

**Table 4. Newcastle–Ottawa assessment of the quality of included studies**

| Study                | Selection | Comparability | Outcome |
|----------------------|-----------|--------------|---------|
| Angelis et al. 2020  | ****      | **           | ***     |
| Dai et al. 2020      | ****      | **           | ***     |
| Grelier et al. 2020  | ****      | *            | ***     |
| Guerini et al. 2020  | ****      | *            | ***     |
| Kabarriti et al. 2020| ****      | **           | ***     |
| Lee et al. 2020      | ****      | **           | ***     |
| Samson et al. 2020   | ****      | *            | ***     |
| Shweta et al. 2020   | ****      | *            | ***     |
| Song et al. 2020     | ****      | *            | ***     |
| Spezzani et al. 2020 | ****      | *            | ***     |
| Vuagnat et al. 2020  | ****      | **           | ***     |
| Zhang et al. 2020    | ****      | **           | ***     |
cancer patients is urgently needed to provide strong evidence from large cohorts that allow for risk-benefit analyses and risk-based frameworks for cancer health care.

Until such registries exist, we should continue to minimise cancer patients’ exposure to and risk from COVID-19 infection by safely optimising hospital visits, finding alternative effective cancer treatment plans and mitigating the risks of immunosuppression in cancer patients. Personalised decisions are crucial, as withholding effective cancer treatments in many cancer patients carries a risk to patients’ health that can outweigh the risk of COVID-19 infection itself.

**Conclusion**

During the COVID-19 era, cancer care plans should be designed after a risk-benefit assessment. Special care is needed while treating elderly patients, as age was found to negatively impact the early mortality rate after COVID-19 infection. Finally, harmonised solid data across the globe are crucial for establishing international guidelines for cancer patients who undergo RT during the COVID-19 era.

**Supplementary material.** For supplementary material accompanying this paper visit [https://doi.org/10.1017/S1460396921000637](https://doi.org/10.1017/S1460396921000637)

**Acknowledgements.** The authors appreciate the support from the Research Medical Library at The University of Texas MD Anderson Cancer Center, especially the great help from Sarah Bronson, ELS, for editing the draft.

**Funding.** None.

**Conflict of Interest.** None of the authors report conflicts of interest.

**References**

1. Worldometer. COVID-19 Coronavirus pandemic. [https://www.worldometers.info/coronavirus/#countries](https://www.worldometers.info/coronavirus/#countries). Accessed on June 15 2021.

2. Organization. W H Coronavirus disease (COVID-19) pandemic. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Accessed on June 15 2021.

3. Anderson R M, Heesterbeek H, Klinkenberg D and Hollingsworth T D. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 2020; 395: 931–934.

4. ASTRO. COVID-19 recommendations to radiation oncology practices. [https://www.astro.org/daily-practice/covid-19-recommendations-and-information](https://www.astro.org/daily-practice/covid-19-recommendations-and-information). Accessed on June 15 2021.

5. Bos A C, van Erming F N, van Gestel Y R et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 2015; 51: 2553–2561.

6. Surgeons. A C O Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. [https://www.facs.org/quality-programs/cancer/executive-summary](https://www.facs.org/quality-programs/cancer/executive-summary). Accessed on June 15 2021.

7. Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335–337.

8. Yu J, OuYang W, Chua M I K and Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China. J Am Med Assoc Oncol 2020; 6: 1108–1110.

9. Epidemiology Working Group for NCIP. Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 145–151.

10. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). [https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf). Accessed on June 15 2021.
presenting with sustained COVID-19 infection. Indian J Palliat Care 2020; 26: S148–S149.

32. Repici A, Maselli R, Colombo M et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know. Gastrointest Endosc 2020; 92: 192–197.

33. Control. E C f D P a Outbreak of novel coronavirus disease 2019 (COVID-19): Increased transmission globally –fifth update. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-outbreak-novel-coronavirus-disease-2019-covid-19-increased. Accessed on June 15 2021.

34. Adams J G, Walls R M. Supporting the health care workforce during the COVID-19 global epidemic. J Am Med Assoc 2020; 323: 1439–1440.

35. Wu J T, Leung K, Leung G M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020; 395: 689–697.

36. Shi H, Han X, Jiang N et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20: 425–434.

37. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062.

38. Liang W-H, Guan W-J, Li C-C et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J 2020; 55: 2000562.

39. Shmushkevich S, Karim N A, Baudo M, et al. Effects of cancer, coronary artery disease and other comorbidities on COVID-19 related mortality: a meta-analysis and meta-regression. J Surg Res 2020; 3: 343–369.

40. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel coronavirus–infected pneumonia in Wuhan, China. J Am Med Assoc 2020; 323: 1061–1069.

41. Dumoulin D W, Gietema H A, Paats M S, Hendriks I E L and Cornelissen R. Differentiation of COVID-19 pneumonia and ICI induced pneumonitis. Front Oncol 2020; 10: 577696.

42. Palma D A, Senan S, Tsujino K et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 85: 444–450.

43. Kong F-M, Haken R T, Eisbruch A and Lawrence T S. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005; 32: 42–54.

44. Lee B M, Chang J S, Kim S Y, Keum K C, Suh C O, Kim Y B. Hypofractionated radiotherapy dose scheme and application of new techniques are associated to a lower incidence of radiation pneumonitis in Breast cancer patients. Front Oncol 2020; 10.

45. Suresh K, Voong K R, Shankar B et al. Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 2018; 13: 1930–1939.

46. Widmann G, Nguyen V A, Plaickner J and Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy, Curr Radiol Rep 2016; 5(11): 59. doi: 10.1007/s40134-017-0256-2.

47. Schönrich G, Raftery M J. The PD-1/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol 2019; 9. https://www.frontiersin.org/articles/10.3389/fcimb.2019.00207/full. Accessed on June 13 2019.

48. Keffer S, Guy C L, Weiss E. Fatal radiation pneumonitis: literature review and case series. Adv Radiat Oncol 2020; 5: 238–249.

49. Haanen J B A G, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv119–iv142.

50. Xu B, Fan C-Y, Wang A-L et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect 2020; 81: e51–e60.

51. He R, Lu Z, Zhang L et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol 2020; 127: 104361.

52. Liu J, Li S, Liu J et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020. doi: 10.1016/j.ebiom.2020.102763.

53. Anil I, Arnold R, Benkwitz-Beford S et al. The UK Coronavirus cancer monitoring project: protecting patients with cancer in the era of COVID-19. Lancet Oncol 2020; 21: 622–624.

54. ESMO. ESMO Guidelines-Cancer patient management during the COVID-19 pandemic. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic. Accessed on June 15 2021.